TLPH Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 1.02
- PEG ratio
- —
- P/B
- 3.61
- P/S (TTM)
- 66431.55
- EV/EBITDA
- 0.11
Profitability & growth
- ROE (TTM)
- -118.4%
- Operating margin
- -1451600.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 0.70
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Talphera Inc.
Company profileTalphera Inc. is a pioneering biotechnology company dedicated to advancing peptide-based therapies for rare diseases and significant unmet medical needs. Its promising pipeline, especially in developing innovative cancer treatments, highlights the firm's potential for substantial growth within the biopharmaceutical industry. Committed to rigorous research and focused on delivering transformative health solutions, Talphera represents a compelling investment opportunity for institutional investors seeking to capitalize on the dynamic biotech landscape.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1850 GATEWAY DRIVE, SAN MATEO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer